Review
Version 1
Preserved in Portico This version is not peer-reviewed
An Update on Self-Amplifying mRNA Vaccine Development
Anna Blakney
Version 1
: Received: 16 December 2020 / Approved: 18 December 2020 / Online: 18 December 2020 (11:12:44 CET)
A peer-reviewed article of this Preprint also exists.
Blakney, A.K.; Ip, S.; Geall, A.J. An Update on Self-Amplifying mRNA Vaccine Development. Vaccines 2021, 9, 97. Blakney, A.K.; Ip, S.; Geall, A.J. An Update on Self-Amplifying mRNA Vaccine Development. Vaccines 2021, 9, 97.
Journal reference: Vaccines 2021, 9, 97
DOI: 10.3390/vaccines9020097
Abstract
This review will explore the four major pillars required for design and development of an saRNA vaccine: antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). In will report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.
Subject Areas
RNA; self-amplifying RNA; replicon; vaccine; drug delivery
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)